Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: For end-users of diabetes models that include UKPDS 82 risk equations, an important question is how well these new equations perform. Consequently, the principal objective of this study was to validate the UKPDS 82 risk equations, embedded within an established type 2 diabetes mellitus (T2DM) model, the Cardiff Diabetes Model, to contemporary T2DM outcomes studies. METHODS: A total of 100 validation endpoints were simulated across treatment arms of twelve pivotal T2DM outcomes studies, simulation cohorts representing each validation study's cohort profile were generated and intensive and conventional treatment arms were defined in the Cardiff Diabetes Model. RESULTS: Overall the validation coefficient of determination was similar between both sets of risk equations: UKPDS 68, R(2) = 0.851; UKPDS 82, R(2) = 0.870. Results stratified by internal and external validation studies produced MAPE of 43.77 and 37.82%, respectively, when using UKPDS 82, and MAPE of 40.49 and 53.92%, respectively when using UKPDS 68. Areas of lack of fit, as measured by MAPE were inconsistent between sets of equations with ACCORD demonstrating a noteworthy lack of fit with UKPPDS 68 (MAPE = 170.88%) and the ADDITION study for UKPDS 82 (MAPE = 89.90%). CONCLUSIONS: This study has demonstrated that the UKPDS 82 equations exhibit similar levels of external validity to the UKPDS 68 equations with the additional benefit of enabling more diabetes related endpoints to be modeled.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“The specific external validation studies included in this analysis were: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) [20]; the Veterans Affairs Diabetes Trial (VADT) [21]; the Action in Diabetes and Vascular Disease: Preterax and Diamicro…”
MethodDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · cited 1×
“The specific external validation studies included in this analysis were: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) [20]; the Veterans Affairs Diabetes Trial (VADT) [21]; the Action in Diabetes and Vascular Disease: Preterax and Diamicro…”
Method
Cited by
McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14162 · Cited by 58
Self-citationMcEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34
Self-citationIgarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01270-8 · Cited by 17
Metadata
- Authors
- McEwan, P., Ward, T., Bennett, H., & Bergenheim, K.
- Venue
- Cost Effectiveness and Resource Allocation
- Published
- 2015-08-04
- Volume
- 13
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1478-7547 (ISSN-L)
- OpenAlex
- W2100764138
- Cited by
- 50
- References
- 10
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. https://app.cochat.ai/papers/10.1186/s12962-015-0038-8
- The paper
- McEwan, P., Ward, T., Bennett, H., & Bergenheim, K. (2015). Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-015-0038-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.